We are live on
!
Find out more
Lyell Immunopharma
LYEL
LYEL
74 hedge funds and large institutions have $251M invested in Lyell Immunopharma in 2026 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 8 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
200% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 8
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
37% more call options, than puts
Call options by funds: $261K | Put options by funds: $191K
9% more funds holding
Funds holding: 68 → 74 (+6)
2.6% less ownership
Funds ownership: 56.95% → 54.35% (-2.6%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
32% less capital invested
Capital invested by funds: $372M → $251M (-$121M)
Holders
74
Holders Change
+6
Holders Change %
+8.82%
% of All Funds
0.91%
Holding in Top 10
8
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-11.11%
% of All Funds
0.1%
New
18
Increased
24
Reduced
8
Closed
9
Calls
$261K
Puts
$191K
Net Calls
+$70K
Net Calls Change
+$1.18M
Top Buyers
Top Sellers
| 1 |
Invesco
Atlanta,
Georgia
|
-$3.04M |
| 2 |
JJ
Johnson & Johnson
New Brunswick,
New Jersey
|
-$1.69M |
| 3 |
RC
RBF Capital
San Francisco,
California
|
-$713K |
| 4 |
Barclays
London,
United Kingdom
|
-$334K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$293K |
